Novel recombinant vaccinia virus-vectored vaccine affords complete protection against homologous Borrelia burgdorferi infection in mice
Open Access
- 11 October 2024
- journal article
- research article
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 13 (1) , 2399949
Abstract
The rising prevalence of Lyme disease (LD) in North America and Europe has emerged as a pressing public health concern. Despite the availability of veterinary LD vaccines, no vaccine is currently available for human use. Outer surface protein C (OspC) found on the outer membrane of the causative agent, Borrelia burgdorferi, has been identified as a promising target for LD vaccine development due to its sustained expression during mammalian infection. However, the efficacy and immunological mechanisms of LD vaccines solely targeting OspC are not well characterized. In this study, we developed an attenuated Vaccinia virus (VV) vectored vaccine encoding type A OspC (VV-OspC-A). Two doses of the VV-OspC-A vaccine conferred complete protection against homologous B. burgdorferi challenge in mice. Furthermore, the candidate vaccine also prevented the development of carditis and lymph node hyperplasia associated with LD. When investigating the humoral immune response to vaccination, VV-OspC-A was found to induce a robust antibody response predominated by the IgG2a subtype, indicating a Th1-bias. Using a novel quantitative flow cytometry assay, we also determined that elicited antibodies were capable of inducing antibody-dependent cellular phagocytosis in vitro. Finally, we demonstrated that VV-OspC-A vaccination generated a strong antigen-specific CD4+ T-cell response characterized by the secretion of numerous cytokines upon stimulation of splenocytes with OspC peptides. This study suggests a promising avenue for LD vaccine development utilizing viral vectors targeting OspC and provides insights into the immunological mechanisms that confer protection against B. burgdorferi infection.Keywords
Funding Information
- Government of Canada
This publication has 60 references indexed in Scilit:
- Role of IL-6 in the commitment of T cell subsetsCytokine, 2021
- VANGUARD®crLyme: A next generation Lyme disease vaccine that prevents B. burgdorferi infection in dogsVaccine: X, 2020
- Application of poxvirus K3 ortholog as a positive selection marker for constructing recombinant vaccinia viruses with modified host rangeMethodsX, 2020
- Clinical spectrum of Lyme diseaseEuropean Journal of Clinical Microbiology & Infectious Diseases, 2018
- T-Cell Immunity2018
- How antibodies use complement to regulate antibody responsesMolecular Immunology, 2014
- Lyme CarditisInfectious Disease Clinics of North America, 2008
- (How) do aluminium adjuvants work?Immunology Letters, 2006
- Histopathological Studies of Experimental Lyme Disease in the DogJournal of Comparative Pathology, 2005
- Effect of Climate Change on Lyme Disease Risk in North AmericaEcohealth, 2005